Lido Advisors LLC grew its position in shares of AbbVie Inc (NYSE:ABBV) by 37.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,294 shares of the company’s stock after buying an additional 4,676 shares during the quarter. Lido Advisors LLC’s holdings in AbbVie were worth $1,560,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also recently made changes to their positions in the company. Hudock Capital Group LLC raised its stake in shares of AbbVie by 109.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after acquiring an additional 806 shares in the last quarter. Ffcm LLC raised its stake in shares of AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after acquiring an additional 963 shares in the last quarter. Bristlecone Advisors LLC bought a new position in shares of AbbVie in the 3rd quarter valued at approximately $113,000. BDO Wealth Advisors LLC bought a new position in shares of AbbVie in the 2nd quarter valued at approximately $115,000. Finally, Hershey Trust Co. bought a new position in shares of AbbVie in the 3rd quarter valued at approximately $139,000. Institutional investors and hedge funds own 69.33% of the company’s stock.
AbbVie Inc (NYSE ABBV) opened at $111.86 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. The company has a market capitalization of $178,688.41, a P/E ratio of 34.00, a price-to-earnings-growth ratio of 1.06 and a beta of 1.60. AbbVie Inc has a 1 year low of $60.15 and a 1 year high of $125.86.
AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 26th. The company reported $1.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.44 by $0.04. The company had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. AbbVie had a return on equity of 152.78% and a net margin of 18.82%. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.20 EPS. equities analysts anticipate that AbbVie Inc will post 7.46 earnings per share for the current year.
ABBV has been the topic of a number of recent analyst reports. Credit Suisse Group set a $135.00 price objective on AbbVie and gave the company a “hold” rating in a research note on Monday, January 29th. Societe Generale raised their price objective on AbbVie in a research note on Tuesday, November 21st. Leerink Swann downgraded AbbVie from an “outperform” rating to a “market perform” rating and set a $127.00 price objective on the stock. in a research note on Monday, January 29th. BMO Capital Markets set a $84.00 price objective on AbbVie and gave the company a “hold” rating in a research note on Thursday, January 11th. Finally, Jefferies Group raised their price objective on AbbVie from $115.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, January 4th. One analyst has rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. AbbVie presently has an average rating of “Buy” and an average target price of $117.26.
In other AbbVie news, insider Laura J. Schumacher sold 145,510 shares of AbbVie stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $96.71, for a total value of $14,072,272.10. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Richard A. Gonzalez sold 218,193 shares of AbbVie stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $94.01, for a total value of $20,512,323.93. Following the completion of the transaction, the chairman now directly owns 492,030 shares in the company, valued at $46,255,740.30. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 450,743 shares of company stock worth $43,153,684. Company insiders own 0.23% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Lido Advisors LLC Increases Stake in AbbVie Inc (ABBV)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/14/lido-advisors-llc-increases-stake-in-abbvie-inc-abbv.html.
AbbVie Company Profile
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.